Company Overview of Amorcyte, LLC.
Amorcyte, LLC. develops cell therapy products for the treatment of cardiovascular diseases. Its product includes AMR-001, a bone marrow-derived, CD34 positive selected stem cell product for the prevention of major adverse cardiac events following acute myocardial infarction. The company was incorporated in 2005 and is based in Allendale, New Jersey. As of October 17, 2011, Amorcyte, LLC. operates as a subsidiary of Neostem, Inc.
4 Pearl Court
Allendale, NJ 07401
Founded in 2005
Key Executives for Amorcyte, LLC.
Chief Executive Officer and Director
Founder and Chief Scientific Officer
Chairman of Neostem and Chief Executive Officer of Neostem
Chief Medical Officer and Managing Director
Senior Vice President of Corporate Development and Licensing
Compensation as of Fiscal Year 2013.
Amorcyte, LLC. Key Developments
Amorcyte, LLC. Receives a Notice of Allowance of Claims from the U.S. Patent and Trademark Office
Mar 13 13
Neostem Inc. announced that Amorcyte, LLC, its wholly owned subsidiary, received a notice of allowance of claims from the U.S. Patent and Trademark office for patent application 13/285,606 covering a method of treating a progressive myocardial injury caused by an ischemic condition and utilizing a multi-dosing regimen. Once granted, this will represent Amorcyte's fourth U.S. patent and sixth patent overall. The important condition that these claims cover is use of AMR-001 for treating ischemia-induced congestive heart failure, a major unmet medical need afflicting 5.8 million patients in the United States alone (with an annual incidence of 660,000) and approximately 20 million patients worldwide. Traditionally, the majority of these people are labeled as "ischemic" in etiology, recent reports from independent research suggest that perhaps all patients have ischemia as a driver of disease, either due to coronary artery disease or microvessel induced ischemia. The company expected to file an IND in 2013 to assess the ability of AMR-001 to arrest the progression of CHF and prevent the associated comorbidities of that disease. Moreover, these claims cover cryopreservation of the AMR-001 product, facilitating global distribution if approved by appropriate regulatory agencies.
Amorcyte, LLC. Presents at EBD Group AG's Biotech showcase 2013, Jan-08-2013 04:15 PM
Dec 18 12
Amorcyte, LLC. Presents at EBD Group AG's Biotech showcase 2013, Jan-08-2013 04:15 PM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.
Amorcyte, LLC. Receives Approval to Continue its PreSERVE AMI Phase 2 Clinical Trial
Aug 15 12
Amorcyte, LLC., a company of Neostem Inc. announced that it received on August 9, 2012 approval to continue its PreSERVE AMI Phase 2 clinical trial following its first interim data and safety review by the Data Safety Monitoring Board (DSMB). The PreSERVE trial is a Phase 2, randomized, placebo controlled, double-blind study expected to include 160 patients at more than 40 clinical sites. The trial's product candidate, AMR-001, is designed to prevent major adverse cardiac events following acute myocardial infarction (AMI). Patient enrollment for the PreSERVE trial began in January 2012 and the company anticipates completing enrollment in 2013 with six months initial data readout near the end of 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|